Reprogramming Imbalanced Macrophage Populations May Play A Key Role In Resolving Cancer And Various Inflammatory Disorders

Shai Novik, Executive Chairman of the Board at Enlivex Therapeutics, Ltd. ENLV, was a guest speaker at Benzinga’s All Access on June 17th, 2022. 

Enlivex Therapeutics is a clinical stage, macrophage reprogramming immunotherapy company developing Allocetra - an off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state.

Watch full interview here

Feature photo 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechPenny StocksHealth CareGeneralBenzinga All AccessEnlivex Therapeutics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!